Eurobio Scientific Overview

  • Year Founded
  • 1962

Year Founded

  • Status
  • Public

  • Employees
  • 290

Employees

  • Stock Symbol
  • ALERS

Stock Symbol

  • Investments
  • 17

  • Share Price
  • $29.23
  • (As of Thursday Closing)

Eurobio Scientific General Information

Description

Eurobio Scientific operates in the fields of in vitro diagnostics and life sciences. In the Diagnostics sector, it supplies hospital and private diagnostic laboratories with instruments and reagents for medical analyses prescribed by physicians. In the Life Sciences sector, it supplies research laboratories of pharmaceutical groups, biotechnology companies, and public institutions with products required for their R&D programmes, including antibodies that it develops and manufactures. Its products and activities include Transplantation, Oncology, Infectious Diseases, and Life Sciences. The Group generates maximum revenue from France.

Contact Information

Formerly Known As
ExonHit Therapeutic, DIAXONHIT
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 7 Avenue de Scandinavie
  • ZA de Courtaboeuf
  • 91940 Les Ulis
  • France
+33 01
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
PAR
Vertical(s)
Corporate Office
  • 7 Avenue de Scandinavie
  • ZA de Courtaboeuf
  • 91940 Les Ulis
  • France
+33 01

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Eurobio Scientific Stock Performance

As of 12-Nov-2026, Eurobio Scientific’s stock price is $29.23. Its current market cap is $294M with 10.1M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$29.23 $29.43 $22.24 - $29.83 $294M 10.1M 3.9K $0.82

Eurobio Scientific Financials Summary

As of 30-Jun-2026, Eurobio Scientific has a trailing 12-month revenue of $201M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 240,724 276,223 270,539 225,520
Revenue 200,941 190,176 167,250 140,673
EBITDA 34,327 30,064 28,118 26,473
Net Income 8,392 5,488 4,326 5,232
Total Assets 491,662 301,590 267,602 349,670
Total Debt 17,156 18,813 10,166 111,270
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Eurobio Scientific Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Eurobio Scientific‘s full profile, request access.

Request a free trial

Eurobio Scientific Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Eurobio Scientific operates in the fields of in vitro diagnostics and life sciences. In the Diagnostics sector, it suppl
Biotechnology
Les Ulis, France
290 As of 2026

London, United Kingdom
 

Basel, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Eurobio Scientific Competitors (16)

One of Eurobio Scientific’s 16 competitors is GSK, a Corporation company based in London, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
GSK Corporation London, United Kingdom
Roche Corporation Basel, Switzerland
AbbVie Corporation North Chicago, IL
Eurofins Genomics Americas Corporation Louisville, KY
Novartis Corporation Basel, Switzerland
You’re viewing 5 of 16 competitors. Get the full list »

Eurobio Scientific Patents

Eurobio Scientific Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
FR-3163370-A1 Cd74 protein inhibitor compound and its uses Pending 18-Jun-2024
WO-2025262077-A1 Cd74 protein inhibitor compound and uses thereof Pending 18-Jun-2024
EP-3449256-B1 Anti-il17 antibody Active 25-Apr-2016
US-11693003-B2 Anti-il17a autoantibodies for treating or reducing the likelihood of occurrence of bone destruction associated with a chronic autoimmune or inflammatory disease Active 25-Apr-2016
EP-3449256-A1 Antiboby anti il17 Active 25-Apr-2016 G01N33/564
To view Eurobio Scientific’s complete patent history, request access »

Eurobio Scientific Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eurobio Scientific Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Eurobio Scientific‘s full profile, request access.

Request a free trial

Eurobio Scientific Investments & Acquisitions (17)

Eurobio Scientific’s most recent deal was a Merger/Acquisition with CareDx (Lab Products Business) for . The deal was made on 30-Jun-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
CareDx (Lab Products Business) 30-Jun-2026 Merger/Acquisition Diagnostic Equipment
Voden Medical Instruments (Life Science Unit) 01-Jul-2025 Merger/Acquisition Distributors (Healthcare)
Quimark 01-Mar-2025 Merger/Acquisition Distributors (Healthcare)
Myriad Genetics (EndoPredict Business Unit) 01-Aug-2024 Merger/Acquisition Diagnostic Equipment
Alpha Biotech (Distributors) 03-Jan-2024 Merger/Acquisition Distributors (Healthcare)
You’re viewing 5 of 17 investments and acquisitions. Get the full list »

Eurobio Scientific ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Eurobio Scientific’s complete esg history, request access »

Eurobio Scientific Exits (1)

Eurobio Scientific’s most recent exit was on 20-Dec-2006 from RedPath Integrated Pathology. The exit was categorized as with 6 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
RedPath Integrated Pathology 20-Dec-2006 Completed
  • 6 buyers
To view Eurobio Scientific’s complete exits history, request access »

Eurobio Scientific Affiliates

Subsidiaries (6)

Name Industry Location Year Founded
GenDx Utrecht, Netherlands 2005
Quimark Milan, Italy 2000
Pathway Diagnostics (UK) Dorking, United Kingdom 1999
GenBio San Diego, CA 1994
TECOmedical (Other Devices and Supplies) Sissach, Switzerland 1984
You’re viewing 5 of 6 affiliates. Get the full list.  »

Eurobio Scientific FAQs

  • When was Eurobio Scientific founded?

    Eurobio Scientific was founded in 1962.

  • Where is Eurobio Scientific headquartered?

    Eurobio Scientific is headquartered in Les Ulis, France.

  • What is the size of Eurobio Scientific?

    Eurobio Scientific has 290 total employees.

  • What industry is Eurobio Scientific in?

    Eurobio Scientific’s primary industry is Biotechnology.

  • Is Eurobio Scientific a private or public company?

    Eurobio Scientific is a Public company.

  • What is Eurobio Scientific’s stock symbol?

    The ticker symbol for Eurobio Scientific is ALERS.

  • What is the current stock price of Eurobio Scientific?

    As of 12-Nov-2026 the stock price of Eurobio Scientific is $29.23.

  • What is the current market cap of Eurobio Scientific?

    The current market capitalization of Eurobio Scientific is $294M.

  • What is Eurobio Scientific’s current revenue?

    The trailing twelve month revenue for Eurobio Scientific is $201M.

  • Who are Eurobio Scientific’s competitors?

    GSK, Roche, AbbVie, Eurofins Genomics Americas, and Novartis are some of the 16 competitors of Eurobio Scientific.

  • What is Eurobio Scientific’s annual earnings per share (EPS)?

    Eurobio Scientific’s EPS for 12 months was $0.82.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process